Business
SOPHiA GENETICS Launches SOPHiA DDM™ for SureSelect Human All Exon v8
New bioinformatic workflow advances analysis capabilities for whole exome assessment and interpretation BOSTON and LAUSANNE, Switzerland, Nov. 1, 2021
About this update from Sophia Genetics Sa
[{"type":"text","content":"New bioinformatic workflow advances analysis capabilities for whole exome assessment and interpretation\n BOSTON and LAUSANNE, Switzerland, Nov. 1, 2021 /PRNewswire/ -- SOPHiA GENETICS SA (Nasdaq: SOPH), the creator of a global data pooling and knowledge sharing platform that advances data-driven medicine, announced today they have extended their SOPHiA DDM™ Universal Whole Exome analytical capabilities to include industry leading exome SureSelect Human All Exon v8 by Agilent. The new SOPHiA GENETICS pipeline is tailored to the unique features of this product to maximize support for Agilent customers in automating their next generation sequencing (NGS) workflows with enhanced, cutting-edge interpretation tools for germline and cancer applications.\n\n \n \n \n \n \n \n\n \nSOPHiA GENETICS' Universal Whole Exome solution delivers a streamlined end-to-end workflow, from sample to variant report, to advance rare and inherited disease research studies using any exome product. The new SOPHiA DDM™ for SureSelect Human All Exon v8 is a fully integrated, FASTQ-to-report bioinformatic workflow for whole exome analysis and interpretation.\nThe SOPHiA DDM™ for SureSelect Human All Exon v8 offers: \nA complete analytical workflow for reduced turnaround time Multiple types of variants detection Tailored analytics for Agilent-specific sample data Uniform and comprehensive gene coverage Knowledge sharing across the SOPHiA Community Improved tertiary analytics An enhanced user experienceThe SOPHiA DDM™ platform supports multiple commercially available exome panels with tailored pipelines and robust analytics for each, enabling uniform coverage of the target region and a streamlined workflow to reduce overall turnaround time and accelerate rare disease characterization.\nTo learn more about how SOPHiA GENETICS data-driven insights are improving diagnosis, treatment, and drug development for patients and the larger medical community, visit www.sophiagenetics.com.\nAbout SOPHiA GENETICS:SOPHiA GENETICS is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. T...